BRINP2-related peptide

Last updated

BRINP2-related peptide
BRINP2-related peptide.svg
Clinical data
Other namesBRINP2-related peptide; BRP
Routes of
administration 		Subcutaneous, Intravenous, Intraperitoneal
Drug class Peptide-based metabolic modulator
Legal status
Legal status
  • Investigational
Pharmacokinetic data
Metabolism Proteolytic degradation (Arg-Arg cleavage site) [1]
Chemical and physical data
Formula C68H117N25O14S
Molar mass 1540.91 g·mol−1
3D model (JSmol)
  • CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(N)=O
  • InChI=1S/C68H117N25O14S/c1-10-37(8)53(93-57(99)43(21-16-24-81-68(76)77)85-62(104)48(29-40-31-78-33-82-40)90-64(106)52(70)38(9)94)65(107)91-46(27-36(6)7)58(100)84-41(19-14-22-79-66(72)73)55(97)83-42(20-15-23-80-67(74)75)56(98)86-44(25-34(2)3)59(101)88-47(28-39-17-12-11-13-18-39)61(103)89-49(30-51(69)95)63(105)87-45(26-35(4)5)60(102)92-50(32-108)54(71)96/h11-13,17-18,31,33-38,41-50,52-53,94,108H,10,14-16,19-30,32,70H2,1-9H3,(H2,69,95)(H2,71,96)(H,78,82)(H,83,97)(H,84,100)(H,85,104)(H,86,98)(H,87,105)(H,88,101)(H,89,103)(H,90,106)(H,91,107)(H,92,102)(H,93,99)(H4,72,73,79)(H4,74,75,80)(H4,76,77,81)/t37-,38+,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,52-,53-/m0/s1
  • Key:HMJIRJDBVYKLDC-KVBBLKIJSA-N

BRINP2-related peptide (BRP) is a peptide developed at Stanford which displays anti-obesity action similar to semaglutide. It does this without significant muscle loss or anxiety and without impacting bowel movement when administered to mice and pigs. [2] BRP primarily stimulates receptors in the hypothalamus and is consistent with GPCR activation leading to stimulation of CREB and Fos activity in neuronal cells. [1]

BRP is a peptide derived from the BRINP2 protein, corresponding to amino acids 386–397 (THRILRRLFNLC) of BRINP2. [1] [3] This 12-amino acid peptide is flanked by KK and KR recognition sites within the BRINP2 protein, which are cleaved by proprotein convertases to release the peptide. BRP has been detected in human cerebrospinal fluid by mass spectrometry. [1] Additionally, BRP undergoes C-terminal amidation, resulting in the sequence THRILRRLFNLC-NH2. The non-amidated form of the peptide is inactive. [1]

References

  1. 1 2 3 4 5 Coassolo L, B Danneskiold-Samsøe N, Nguyen Q, Wiggenhorn A, Zhao M, Wang DC, et al. (March 2025). "Prohormone cleavage prediction uncovers a non-incretin anti-obesity peptide". Nature. doi:10.1038/s41586-025-08683-y. PMID   40044869.
  2. ↑ Conger K (5 March 2025). "Stanford scientists develop potential Ozempic alternative". Stanford Medicine News. Retrieved 8 March 2025.
  3. ↑ WO 2024/030214,Svensson KJ, Voilquin L,"Brinp2-Derived Peptide Compositions for Treating Obesity and Weight Management",published 8 February 2024, assigned to The Board of Trustees of the Leland Stanford Junior University.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.